Evidence map›Paper›PMID 24040459›Full record

ReviewInternational journal of clinical and experimental pathology2013

Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature.

Asami Shimada, Kei-Ji Sugimoto, Mutsumi Wakabayashi, Hidenori Imai, Yasunobu Sekiguchi, Noriko Nakamura, Tomohiro Sawada, Yasunori Ota, Norio Komatsu, Masaaki Noguchi

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in International journal of clinical and experimental pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Asami ShimadaDepartment of Hematology, Juntendo University Urayasu Hospital Urayasu, Japan.
Kei-Ji Sugimoto
Mutsumi Wakabayashi
Hidenori Imai
Yasunobu Sekiguchi
Noriko Nakamura
Tomohiro Sawada
Yasunori Ota
Norio Komatsu
Masaaki Noguchi
Juntendo University Urayasu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 85-year-old man presented with pain and numbness in the left buttock, and physical examination revealed an approximately 7 cm mass extending from the first to the third sacral vertebrae; biopsy of the mass led to the diagnosis of CD10-negative, BCL6-weakly positive, MUM1-positive, non-germinal center (non-GC) type diffuse large B-cell lymphoma (DLBCL). Furthermore, serological testing showed negative results for Epstein-Barr virus (EBV) infection, and fluorescence in situ hybridization (FISH) revealed a MYC translocation. Radiographs showed no remarkable osteolytic bone destruction, and the patient was staged with Stage IAE. After 8 cycles of rituximab therapy and 6 cycles of CHOP therapy, complete remission has been maintained until now, approximately 1 year after the treatment. Primary sacral lymphoma is very rare, with only 6 reported cases, including the present one. A review of the reported cases revealed that the disease predominantly affects elderly men, is usually non-GC-type DLBCL and stage IAE, measures approximately 2-7 cm in diameter in general, and does not show early recurrence after chemotherapy or chemoradiotherapy. There is no report in the literature yet of primary sacral DLBCL with MYC translocation, and this is the first case report. On the other hand, 35 cases of CD10-negative DLBCL with MYC translocation, including the present one, have been reported, and a review of the reported cases showed that the disease predominantly affects Asians, middle-aged or elderly men, shows positivity for either BCL6 or MUM1 and negativity for EBV, and has a high international prognostic index and poor prognosis.

Indexed as

SacrumTranslocation, GeneticAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsyGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMalePhenotypePositron-Emission TomographyProto-Oncogene Proteins c-mycBiomarkers, TumorMYC protein, humanProto-Oncogene Proteins c-mycCD10-negativeMYCnon-germinal center DLBCLparaffin-embedded tissue section-fluorescence in-situ hybridizationPrimary sacral lymphoma

Identifiers

PMID24040459
PMCPMC3759501
OpenAlexW1590486237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.